About emicizumab
Bispecific monoclonal antibody; clotting factor VIII mimetic
Used for
- Routine prevention of bleeding in hemophilia A with or without factor VIII inhibitors.
Usual adult dose
Loading: 3 mg/kg under the skin weekly for four weeks; then 1.5 mg/kg weekly, 3 mg/kg every two weeks, or 6 mg/kg every four weeks.
Usual dose in children
Same weight-based schedule as adults; used in children of all ages, including newborns.
Common side effects
- Injection-site reactions
- Headache
- Joint pain
- Diarrhea
Important warnings
- Thrombotic microangiopathy and blood clots can occur with activated prothrombin complex concentrate.
- Avoid activated prothrombin complex concentrate when possible; follow specialist guidance if needed.
- Emicizumab interferes with some clotting tests, including activated partial thromboplastin time.
- This medicine does not treat an active bleed.
Pregnancy
Human pregnancy data are limited; use only when potential benefit justifies potential risk.
Breastfeeding
It is unknown whether emicizumab enters breast milk; discuss benefits and potential risks.
Interactions
- Activated prothrombin complex concentrate can increase risk of blood clots and thrombotic microangiopathy.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.